GICS Sector : Healthcare
Viatris Inc.operates as a healthcare company worldwide.The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
Viatris delivered a robust financial performance in Q3 2025, with total revenues of $3.76 billion, down 1% versus the prior year, but operational revenue growth was 1% excluding the Indore impact. Adjusted gross margin was 56%, in line with expectations, but impacted by the Indore issue. The company's actual EPS came out at $0.67, beating estimates of $0.63. Free cash flow generation remained strong at $658 million, or $728 million excluding transaction-related costs, enabling significant share buybacks and returning over $920 million to shareholders year-to-date.
Publication Date: Nov -10
The company's commercial performance was strong across its portfolio, particularly in Europe, emerging markets, and the Greater China region. Net sales decreased 9% in Japan, primarily due to government price regulations and a change in reimbursement policy affecting off-patent brands. However, Greater China saw positive momentum with net sales exceeding expectations and growing 9%. As Theodora Mistras mentioned, the company expects the underlying positive fundamentals to continue into 2026, with new product contribution expected to be in the range of $450 million to $550 million.
Viatris' pipeline is advancing at a strong pace, with several highlights, including the fast-acting meloxicam, which is expected to be submitted for NDA by the end of the year. The company is optimistic about its potential, with peak sales potentially reaching $0.5 billion. Additionally, the low-dose estrogen weekly patch is under FDA review, and sotagliflozin filings have been made in multiple markets around the world.
Using the current valuation metrics, Viatris' P/E Ratio stands at -3.19, P/B Ratio at 0.77, and P/S Ratio at 0.83. The company's Dividend Yield is 4.74%, and Free Cash Flow Yield is 14.13%. Analysts estimate next year's revenue growth at 1.2%. These metrics indicate that the company is priced in for a certain level of growth, and the upcoming year will be crucial in determining whether Viatris can meet these expectations.
The company is undertaking an enterprise-wide strategic review, aiming to deliver meaningful cost savings. The quantum of savings is expected to be significant, with a focus on commercial sales, marketing, product mix, R&D, and more. The company plans to reinvest some of the savings to drive future growth, and will be transparent about the quantum of savings and phasing in Q1.
Mark Cuban Takes Aim at FDA Fees
Dec -04
Viatris Inc. (VTRS) Presents at Evercore 8th Annual Healthcare Conference Transcript
Dec -03
Viatris Inc. (VTRS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Dec -02
Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration
Dec -01
Viatris to Participate in Upcoming Investor Conferences
Nov -24
Európska štúdia zisťuje klesajúce ceny, rastúce náklady a nedostatky - Viatris a Medicines for Europe prezentujú nezávislú štúdiu počas Svetového týždňa povedomia o antimikrobiálnej rezistencii (AMR)
Nov -20
Europäische Studie zeigt sinkende Preise, steigende Kosten und Engpässe - Ergebnisse einer unabhängigen Studie, die während der World AMR Awareness Week von Viatris und Medicines for Europe vorgestellt wurden
Nov -20
Europejskie badanie pokazuje spadające ceny, rosnące koszty i niedobory - wyniki niezależnego badania przedstawione podczas Światowego Tygodnia Wiedzy o Antybiotykach przez firmę Viatris i organizację Medicines for Europe
Nov -20
Viatris Inc.'s brands with 3% growth are driven by increasing demand for generic and complex generics, expansion into emerging markets, and a strong product pipeline. Additionally, strategic partnerships, cost savings initiatives, and effective supply chain management contribute to their growth.
Viatris Inc.'s generics segment growth is driven by increasing demand for affordable medicines, patent expirations of blockbuster drugs, and strategic acquisitions. Additionally, the company's global presence, diversified product portfolio, and operational efficiencies contribute to its growth momentum.
Viatris offers a range of biosimilar products, which are highly similar to reference biologics, providing affordable and accessible treatment options for patients.
Viatris develops and commercializes complex generic products, including inhalers, injectables, and transdermal patches, offering cost-effective alternatives to branded products.
Viatris has a portfolio of branded products, including Wixela Inhub, a generic version of Advair Diskus, and Norvir, a protease inhibitor for HIV treatment.
Viatris offers a range of OTC products, including vitamins, minerals, and supplements, providing consumers with affordable healthcare solutions.
Viatris provides CDMO services, offering expertise in development, manufacturing, and packaging of pharmaceutical products.
Viatris Inc. faces moderate threat from substitutes due to the presence of alternative treatments and generic drugs in the market.
Viatris Inc. has a diverse customer base, which reduces the bargaining power of individual customers, making it a low threat.
Viatris Inc. relies on a few key suppliers for raw materials, which gives them some bargaining power, making it a moderate threat.
The pharmaceutical industry has high barriers to entry, including regulatory hurdles and significant capital requirements, making it a low threat for Viatris Inc.
The pharmaceutical industry is highly competitive, with many established players, making the intensity of rivalry a high threat for Viatris Inc.
| Value | |
|---|---|
| Debt Weight | 47.09% |
| Debt Cost | 9.58% |
| Equity Weight | 52.91% |
| Equity Cost | 9.58% |
| WACC | 9.58% |
| Leverage | 88.99% |
Value: 1.9
Growth: 9.3
Quality: 8.3
Yield: 0.0
Momentum: 8.0
Volatility: 7.0
1-Year Total Return ->
Value: 8.9
Growth: 2.2
Quality: 3.3
Yield: 7.0
Momentum: 3.0
Volatility: 7.3
1-Year Total Return ->
Value: 6.0
Growth: 7.1
Quality: 5.1
Yield: 0.0
Momentum: 10.0
Volatility: 3.3
1-Year Total Return ->
Value: 3.9
Growth: 3.7
Quality: 6.0
Yield: 0.0
Momentum: 7.5
Volatility: 5.3
1-Year Total Return ->
Value: 5.8
Growth: 9.0
Quality: 7.9
Yield: 0.0
Momentum: 0.0
Volatility: 2.7
1-Year Total Return ->
Value: 6.2
Growth: 6.1
Quality: 5.0
Yield: 0.0
Momentum: 5.0
Volatility: 1.0
1-Year Total Return ->